|
USA-MA-SUDBURY Azienda Directories
|
Azienda News:
- ClinicalTrials. gov
Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information Search for terms
- Clinical Trial: NCT02468024 - My Cancer Genome
cohort studies to be effective at controlling primary early lung cancer Recent pooled analysis of both the STARS and ROSEL randomized trials comparing SABR versus lobectomy have shown a significantly improved 3-year survival with SABR, giving further impetus for successful completion of a randomized trial
- Lung Surgery and Radiation therapy in Non-Small Cell Lung Cancer . . .
JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
- NCT02468024: An ongoing trial by University of Texas . . . - TrialsTracker
Built by the Bennett Institute for Applied Data Science, University of Oxford Data last updated 2 April 2025 Next planned update 4 April 2025 Problems? Feedback? Get in touch
- ROMANBY COURT MANAGEMENT COMPANY LIMITED
What's included in the company snapshot? Use this service to order a signed certificate of incorporation, which can include key details about the company and a statement of good standing Use this
- West Cancer Center
Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!
- ROMANBY COURT MANAGEMENT COMPANY LIMITED - Companies House
Company number 02468024 Follow this company File for this company Company Overview for ROMANBY COURT MANAGEMENT COMPANY LIMITED (02468024)
- Nicholas Robert William SILLS - Companies House
ROMANBY COURT MANAGEMENT COMPANY LIMITED (02468024) Company status Active Correspondence address Flat 10 Romanby Court, 31 Mill Street, Redhill, Surrey, United Kingdom, RH1 6PA Role Active Director Appointed on 19 March 2023
- STABLE-MATES - Victorian Cancer Trials Link
Stereotactic Ablative Radiotherapy (SABR) has been shown to be effective at controlling primary early lung cancer Recent analysis of previous clinical trials comparing SABR versus lobectomy (a surgical procedure where one of the lobes of the lung is removed) have shown a significant improvement in 3-year survival with SAB
- Landmark Trials in Lung Cancer - SpringerLink
NCT 02468024 (STABLE-MATES) A Randomized Phase III Study of Sub-lobar Resection Versus Stereotactic Ablative Radiotherapy in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial Primary outcome measure is overall survival Estimated enrollment is 272 patients
|
|